Isoflavone Glycosides as Peroxisome Proliferator-Activated Receptor-alpha Modulator
    1.
    发明申请
    Isoflavone Glycosides as Peroxisome Proliferator-Activated Receptor-alpha Modulator 审中-公开
    异黄酮糖苷作为过氧化物酶体增殖物激活受体-α调节剂

    公开(公告)号:US20090099099A1

    公开(公告)日:2009-04-16

    申请号:US11872771

    申请日:2007-10-16

    IPC分类号: A61K31/7048 C07H3/02 A61P3/04

    CPC分类号: C07H3/02

    摘要: A method of treating or preventing diseases related to modulation of PPAR-α in comprising administering to a human or other mammals in need of such treatment an effective amount of plant material derived from plants of the genera Puerila Lobata.

    摘要翻译: 一种治疗或预​​防与PPAR-α调节有关的疾病的方法,其包括对需要这种治疗的人或其他哺乳动物施用有效量的源自普拉里巴拉杜鹃属植物的植物材料。

    Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof
    2.
    发明授权
    Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof 有权
    低氧选择性弱碱性2-硝基咪唑递送剂及其使用方法

    公开(公告)号:US07842278B2

    公开(公告)日:2010-11-30

    申请号:US11588634

    申请日:2006-10-27

    IPC分类号: A61K51/00 A61M36/14

    摘要: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.

    摘要翻译: 本发明具有一类具有二级碱性氮原子的2-硝基咪唑化合物和具有一种或多种治疗剂,细胞毒性剂,可检测标记或螯合基团的连接体。 特别地,本发明提供了含有用于硼中子捕获治疗(BNCT)的硼原子簇的2-硝基咪唑化合物。 2-硝基咪唑化合物可用于治疗缺氧条件,包括例如癌症,炎症和局部缺血。 弱碱性2-硝基咪唑化合物靶向缺氧组织,并提供总体增加的组织浓度。

    Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia
    3.
    发明授权
    Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia 有权
    弱碱性2-硝基咪唑用于非侵入性检测组织缺氧

    公开(公告)号:US09056136B2

    公开(公告)日:2015-06-16

    申请号:US11544698

    申请日:2006-10-06

    摘要: The present invention incorporates weakly basic substituents (pKa about 8 or greater) such as pyrrolidine, piperidine, piperazine and azapane moieties in halogenated 2-nitromidazoles for the non-invasive detection of cellular hypoxia in normal and malignant tissues. The compounds of the invention can be used in 18F positron emission tomography, 19F magnetic resonance spectroscopy, and 19F magnetic resonance imaging.

    摘要翻译: 本发明在卤代2-硝唑咪唑中引入弱碱性取代基(pKa约8个或更大),例如吡咯烷,哌啶,哌嗪和氮杂环戊烷部分,用于非侵入性检测正常和恶性组织中的细胞缺氧。 本发明的化合物可用于18F正电子发射断层扫描,19F磁共振光谱和19F磁共振成像。

    Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia
    4.
    发明申请
    Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia 有权
    弱碱性2-硝基咪唑用于非侵入性检测组织缺氧

    公开(公告)号:US20080085237A1

    公开(公告)日:2008-04-10

    申请号:US11544698

    申请日:2006-10-06

    IPC分类号: A61K51/00

    摘要: The present invention incorporates weakly basic substituents (pKa about 8 or greater) such as pyrrolidine, piperidine, piperazine and azapane moieties in halogenated 2-nitromidazoles as a major improvement over prior art for the non-invasive detection of cellular hypoxia in normal and malignant tissues. The invention features the use of [18F] positron emission tomography, [19F] magnetic resonance spectroscopy, and [19F] magnetic resonance imaging. Improvements over prior art compounds are six-fold. 1) Salts of weakly basic reagents are highly water-soluble which facilitates administration. 2) Unreacted reagents are rapidly cleared from systemic circulation thereby decreasing background noise. 3) Reagents with weakly basic substituents are concentrated in tissue ˜3 fold above plasma levels thereby increasing binding intensity and enhancing signal detection. 4) Conjugate bases of weakly basic reagents have intermediate octanol-water partition coefficients that facilitate their penetration into all tissues including brain. 5) Cellular adducts of reagents containing weakly basic substituents are more stable than reagents of prior art. 6) Reagents with weakly basic substituents are effective for the detection of transient hypoxia in solid tissue.

    摘要翻译: 本发明在卤代2-硝基咪唑中含有弱碱性取代基(pKa约8或更大)如吡咯烷,哌啶,哌嗪和氮杂环戊烷部分,作为用于非侵入性检测正常和恶性组织中的细胞缺氧的现有技术的主要改进 。 本发明的特征在于使用[18F]正电子发射断层扫描,[19F]磁共振光谱和[19F]磁共振成像。 对现有技术化合物的改进是六倍。 1)弱碱性试剂的盐是高度水溶性的,有利于给药。 2)未反应的试剂迅速从全身循环中清除,从而降低背景噪音。 3)具有弱碱性取代基的试剂在组织中浓缩至血浆水平以上3倍,从而增加结合强度并增强信号检测。 4)弱碱性试剂的共轭碱具有中间辛醇 - 水分配系数,有助于其渗入包括脑在内的所有组织。 5)含有弱碱性取代基的试剂的细胞加合物比现有技术的试剂更稳定。 6)具有弱碱性取代基的试剂对于检测固体组织中的短暂性缺氧是有效的。

    Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof
    5.
    发明授权
    Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof 有权
    低氧选择性弱碱性2-硝基咪唑递送剂及其使用方法

    公开(公告)号:US08518371B2

    公开(公告)日:2013-08-27

    申请号:US12955720

    申请日:2010-11-29

    IPC分类号: A61K51/00 A61M36/14

    摘要: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.

    摘要翻译: 本发明具有一类具有二级碱性氮原子的2-硝基咪唑化合物和具有一种或多种治疗剂,细胞毒性剂,可检测标记或螯合基团的连接体。 特别地,本发明提供了含有用于硼中子捕获治疗(BNCT)的硼原子簇的2-硝基咪唑化合物。 2-硝基咪唑化合物可用于治疗缺氧条件,包括例如癌症,炎症和局部缺血。 弱碱性2-硝基咪唑化合物靶向缺氧组织,并提供总体增加的组织浓度。

    HYPOXIA-SELECTIVE, WEAKLY BASIC 2-NITROIMIDAZOLE DELIVERY AGENTS AND METHODS OF USE THEREOF
    6.
    发明申请
    HYPOXIA-SELECTIVE, WEAKLY BASIC 2-NITROIMIDAZOLE DELIVERY AGENTS AND METHODS OF USE THEREOF 有权
    HYPOXIA-选择性,弱碱性2-硝基咪唑交付剂及其使用方法

    公开(公告)号:US20110085975A1

    公开(公告)日:2011-04-14

    申请号:US12955720

    申请日:2010-11-29

    摘要: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.

    摘要翻译: 本发明具有一类具有二级碱性氮原子的2-硝基咪唑化合物和具有一种或多种治疗剂,细胞毒性剂,可检测标记或螯合基团的连接体。 特别地,本发明提供了含有用于硼中子捕获治疗(BNCT)的硼原子簇的2-硝基咪唑化合物。 2-硝基咪唑化合物可用于治疗缺氧条件,包括例如癌症,炎症和局部缺血。 弱碱性2-硝基咪唑化合物靶向缺氧组织,并提供总体增加的组织浓度。

    Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof
    7.
    发明申请
    Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof 有权
    低氧选择性弱碱性2-硝基咪唑递送剂及其使用方法

    公开(公告)号:US20080102026A1

    公开(公告)日:2008-05-01

    申请号:US11588634

    申请日:2006-10-27

    摘要: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.

    摘要翻译: 本发明具有一类具有二级碱性氮原子的2-硝基咪唑化合物和具有一种或多种治疗剂,细胞毒性剂,可检测标记或螯合基团的连接体。 特别地,本发明提供了含有用于硼中子捕获治疗(BNCT)的硼原子簇的2-硝基咪唑化合物。 2-硝基咪唑化合物可用于治疗缺氧条件,包括例如癌症,炎症和局部缺血。 弱碱性2-硝基咪唑化合物靶向缺氧组织,并提供总体增加的组织浓度。